July 15 (Reuters) - GlaxoSmithKline GSK.L said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.
GSK agreed to buy U.S. cancer specialist Tesaro for $5.1 billion in December, giving it a marketed product for ovarian cancer, Zejula, which belongs to a promising class of medicines.
The drugmaker said the study met its primary endpoint of a statistically significant improvement in progression free survival for women regardless of their biomarker status.
(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Arun Koyyur)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.